Accession Number
DB00107  (BTD00016, BIOD00016)
Approved, Vet approved
Biologic Classification
Protein Based Therapies

Synthetic 9 residue cyclic peptide. The hormone is prepared synthetically to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity.

Protein structure
Protein chemical formula
Protein average weight
1007.187 Da
>DB00107 sequence
Download FASTA Format
  • Oxitocina
  • Oxytocin
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OxytocinInjection10 [USP'U]/1mLIntramuscular; IntravenousWest Ward Pharmaceutical1980-04-29Not applicableUs
OxytocinInjection, solution10 [USP'U]/1mLIntramuscular; IntravenousFresenius Kabi2000-08-10Not applicableUs
OxytocinInjection, solution10 [USP'U]/1mLIntramuscular; IntravenousCardinal Health2000-08-10Not applicableUs
OxytocinInjection10 [USP'U]/1mLIntramuscular; IntravenousWest Ward Pharmaceutical1980-04-29Not applicableUs
OxytocinInjection, solution10 [USP'U]/1mLIntramuscular; IntravenousCardinal Health2000-08-10Not applicableUs
OxytocinInjection10 [USP'U]/1mLIntramuscular; IntravenousBaxter Laboratories1990-09-302013-02-27Us
Oxytocin Inj 10unit/ml USPLiquid10 unitIntramuscular; IntravenousLyphomed, Division Of Fujisawa Canada Inc.1988-12-311996-09-10Canada
Oxytocin InjectionSolution10 unitIntramuscular; IntravenousFresenius Kabi1996-08-14Not applicableCanada
Oxytocin Injection USPSolution10 unitIntramuscular; IntravenousPfizer1981-12-31Not applicableCanada
PitocinInjection10 [iU]/1mLIntravenousPar Pharmaceutical2018-05-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OxytocinInjection10 [iU]/1mLIntravenousPar Pharmaceutical2012-06-012015-07-13Us
OxytocinInjection10 [USP'U]/1mLIntravenousTeva Parenteral Medicines, Inc.2008-01-242011-04-30Us
OxytocinInjection, solution10 [USP'U]/1mLIntramuscular; IntravenousSagent Pharmaceuticals2018-04-012018-07-19Us
OxytocinInjection10 [USP'U]/1mLIntramuscular; IntravenousWest Ward Pharmaceutical2013-02-13Not applicableUs
OxytocinInjection10 [USP'U]/1mLIntramuscular; IntravenousHikma Farmaceutica2009-08-012014-10-01Us
OxytocinInjection10 [iU]/1mLIntravenousPar Pharmaceutical2012-06-012015-04-30Us
OxytocinInjection100 [USP'U]/10mLIntravenousTeva Parenteral Medicines, Inc.2008-01-242011-02-28Us
OxytocinInjection10 [USP'U]/1mLIntramuscular; IntravenousWest Ward Pharmaceutical2013-02-13Not applicableUs
OxytocinInjection100 [USP'U]/10mLIntramuscular; IntravascularHikma Farmaceutica2009-08-012014-10-01Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
OxytocinOxytocin (2 [USP'U]/100mL)Injection, solutionIntravenousCantrell Drug Company2011-10-20Not applicableUs
OxytocinOxytocin (30 [USP'U]/500mL)Injection, solutionIntravenousCantrell Drug Company2011-10-20Not applicableUs
OxytocinOxytocin (10 [USP'U]/500mL)Injection, solutionIntravenousCantrell Drug Company2011-10-202012-11-12Us
OxytocinOxytocin (20 [USP'U]/1000mL)Injection, solutionIntravenousCantrell Drug Company2011-10-202015-01-14Us
OxytocinOxytocin (10 [USP'U]/1000mL)Injection, solutionIntravenousCantrell Drug Company2012-07-30Not applicableUs
OxytocinOxytocin (20 [USP'U]/500mL)Injection, solutionIntravenousCantrell Drug Company2016-03-18Not applicableUs
OxytocinOxytocin (30 [USP'U]/500mL)Injection, solutionIntravenousCantrell Drug Company2011-10-20Not applicableUs
OxytocinOxytocin (30 [USP'U]/500mL)Injection, solutionIntravenousCantrell Drug Company2011-07-01Not applicableUs
OxytocinOxytocin (10 [USP'U]/500mL)Injection, solutionIntravenousCantrell Drug Company2011-10-202012-11-09Us
OxytocinOxytocin (30 [USP'U]/1000mL)Injection, solutionIntravenousCantrell Drug Company2016-03-18Not applicableUs
International/Other Brands
Pitocin / Syntocinon (Sandoz)
CAS number



Used for labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability. Oxytocin cannot be used for elective induction of labor, there must be a clear medical requirement.

Associated Conditions
Associated Therapies

Indirectly stimulates contraction of uterine smooth muscle by increasing the sodium permeability of uterine myofibrils. Increases contraction amplitude and frequency, which tends to decrease cervical activity, produce dilation and effacement of the cervix, and transiently impede uterine blood flow; contractions produced by oxytocin at term are similar to those occurring during spontaneous labor. High estrogen concentrations lower the threshold for uterine response to oxytocin. Uterine response increases with the duration of pregnancy and is greater in labor than when not in labor; only very large doses elicit contractions in early pregnancy. Contracts myoepithelial cells surrounding the alveoli of the breasts, forcing milk from the alveoli into the larger ducts and facilitating milk ejection. Minimal antidiuretic activity relative to vasopressin; water intoxication possible at high doses and/or excessive electrolyte-free fluid.

Mechanism of action

Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+-dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+, which in turn activates myosin's light chain kinase.. Oxytocin has specific receptors in the muscle lining of the uterus and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term.

AOxytocin receptor
UOxytocin-neurophysin 1

Uterine response after IV administration is immediate and subsides after 1 hour. Uterine contractions occur 3-5mins after IM administration and decreases within 2-3 hours. When 100-200milliunits is administered IV, contractions of the myoepithelial tissue surrounding the alveoli of the breasts occur within minutes and last for about 20 mins.

Volume of distribution

Distributes throughout the extracellular fluid and crosses the placenta. It is probable that it also distributes into milk in small amounts.

Protein binding



Oxytocin is rapidly metabolized in the liver and also in the plasma by oxytocinases. It is also metabolized to a smaller degree by the mammary glands.

Route of elimination

Biliary and renal (excreted unchanged in the urine)

Half life

1-6 min, this is decreased in late pregnancy and during lactation.

Not Available

Oxytocin can produce a severe water intoxication due to its antidiuretic effect. Prolonged IV infusions of more 40milliunits/min are usually the cause. Severe water intoxication with convulsions, coma, and death can occur. Some neonatal seizures have also been reported. Consider potential for water intoxication, particularly when administered by IV infusion and patient is receiving oral fluids. Uterine effects: High doses or hypersensitivity to oxytocin may cause uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus. There have also been reported allergic and anaphylactic reactions to oxytocin but they were rarely fatal.

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
AbexinostatThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acebutolol.
AceprometazineThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aceprometazine.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acetyldigoxin.
AcrivastineThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acrivastine.
AdenosineThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Adenosine.
AjmalineThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ajmaline.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alfuzosin.
AlimemazineThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alimemazine.
AmantadineThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amantadine.
Food Interactions
Not Available


Synthesis Reference

Kerstin Uvnas-Moberg, Thomas Lundeberg, "Use of substances having oxytocin activity for preparation of medicaments for wound healing." U.S. Patent US6262021, issued August, 1988.

General References
  1. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E: Oxytocin increases trust in humans. Nature. 2005 Jun 2;435(7042):673-6. [PubMed:15931222]
  2. Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, Yanagisawa T, Kimura T, Matzuk MM, Young LJ, Nishimori K: Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16096-101. Epub 2005 Oct 25. [PubMed:16249339]
  3. Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W, Davidson JM: Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab. 1987 Jan;64(1):27-31. [PubMed:3782434]
  4. Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J: Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9550-5. Epub 2002 Jul 1. [PubMed:12093924]
  5. Jankowski M, Danalache B, Wang D, Bhat P, Hajjar F, Marcinkiewicz M, Paquin J, McCann SM, Gutkowska J: Oxytocin in cardiac ontogeny. Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13074-9. Epub 2004 Aug 17. [PubMed:15316117]
  6. Link [Link]
External Links
KEGG Compound
PubChem Substance
Therapeutic Targets Database
Guide to Pharmacology
GtP Drug Page
RxList Drug Page Drug Page
ATC Codes
H01BB02 — OxytocinG02AC01 — Methylergometrine and oxytocin
AHFS Codes
  • 76:00.00 — Oxytocics

Clinical Trials

Clinical Trials
0CompletedBasic ScienceFacial Expressions1
0CompletedBasic ScienceHealthy Volunteers5
0CompletedBasic SciencePsychology, Social3
0CompletedBasic ScienceSocial Activity1
0CompletedBasic ScienceSocial Perception1
0CompletedOtherEating Behavior1
0CompletedOtherOverweight and Obesity1
0CompletedPreventionHealthy Volunteers1
0CompletedTreatmentCardiac Dysrhythmia1
0CompletedTreatmentMagnetoencephalography (MEG) / Oxytocin / Schizophrenic Disorders / Social Cognition1
0CompletedTreatmentMethadone Treatment / Opioid Dependence / Substance Abuse1
0CompletedTreatmentOxytocin / Schizophrenic Disorders / Social Cognition1
0CompletedTreatmentPostprocedural Delayed Gastric Emptying1
0RecruitingBasic ScienceHealthy Volunteers1
0RecruitingBasic SciencePosttraumatic Stress Disorders1
0RecruitingOtherAnorexia Nervosa (AN)1
0RecruitingPreventionHealthy Volunteers1
0RecruitingTreatmentAlcohol Dependence / Post Traumatic Stress Disorder (PTSD)1
0RecruitingTreatmentFunctional Magnetic Resonance Imaging (fMRI) / Oxytocin / Schizophrenic Disorders / Social Cognition1
0RecruitingTreatmentOxytocin / Psychotic Disorder NOS / Schizophrenic Disorders / Social Cognition1
0SuspendedBasic ScienceCongenital Prosopagnosia / Healthy Volunteers1
0Unknown StatusBasic ScienceExpressed Emotion / Social Cognition1
0WithdrawnBasic ScienceDyssocial Behavior1
1Active Not RecruitingOtherAutistic Disorder1
1Active Not RecruitingOtherUnit Cohesion1
1CompletedBasic ScienceAlcohol Dependence / Alcohol Related Disorders1
1CompletedBasic ScienceEmotion Regulation / Emotions / Parent-Child Relations1
1CompletedBasic ScienceHealthy Male Adults1
1CompletedBasic ScienceHealthy Male Volunteers3
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceOxytocin Effect on Memory Performance During Phase 1 / Oxytocin Effect on Memory Performance During Phase 2 / Oxytocin Effect on Memory Performance During Phase 3 / Oxytocin Effect on Memory Performance During Phase 41
1CompletedBasic ScienceSustained Positive Behavior Change / Sustained Positive Emotions1
1CompletedDiagnosticAutism Spectrum Conditions/Disorders1
1CompletedOtherAutism Spectrum Conditions/Disorders / Schizophrenic Disorders1
1CompletedOtherCocaine Use Disorders / Opioid Use Disorders1
1CompletedPreventionCesarean Section1
1CompletedPreventionPost Partum Hemorrhage1
1CompletedTreatmentAlcohol Use Disorders (AUD)1
1CompletedTreatmentAutism, Early Infantile1
1CompletedTreatmentFrontotemporal Dementia1
1CompletedTreatmentHealthy Males1
1CompletedTreatmentPostpartum Haemorrhage (PPH)1
1CompletedTreatmentPrader Willi Syndrome1
1CompletedTreatmentSchizophrenic Disorders1
1Not Yet RecruitingOtherAlcohol Dependence1
1RecruitingNot AvailableAutism Spectrum Conditions/Disorders1
1RecruitingBasic ScienceAutism Spectrum Conditions/Disorders / Bipolar Disorder (BD) / Borderline Personality Disorder (BPD) / BPD / Schizoaffective Disorders / Schizophrenic Disorders / Schizotypal Personality Disorder / SPD1
1RecruitingBasic ScienceOxytocin1
1RecruitingBasic SciencePain NOS1
1RecruitingBasic SciencePregnancy / Substance Abuse Problem1
1RecruitingHealth Services ResearchPostpartum Haemorrhage (PPH)1
1RecruitingOtherAmphetamine Use Disorders1
1RecruitingPreventionPostpartum Haemorrhage (PPH)1
1RecruitingTreatmentPostpartum Haemorrhage (PPH)1
1TerminatedTreatmentEmbryo Transfer1
1Unknown StatusNot AvailableOpiate Dependence1
1Unknown StatusTreatmentDepression / Major Depressive Disorder (MDD)1
1WithdrawnBasic ScienceAutism Disorder1
1WithdrawnOtherHealthy Women of Child Bearing Potential1
1, 2CompletedBasic ScienceAutism Spectrum Conditions/Disorders1
1, 2CompletedBasic SciencePrader-Willi Syndrome1
1, 2CompletedBasic ScienceSocial Anxiety Disorder (SAD)1
1, 2CompletedPreventionPostpartum Haemorrhage (PPH)1
1, 2CompletedTreatmentPrader Willi Syndrome1
1, 2CompletedTreatmentPrader-Willi Syndrome1
1, 2Enrolling by InvitationTreatmentOpiate withdrawal symptoms / Opioid Dependence1
1, 2RecruitingBasic ScienceAging / BMI >30 kg/m2 / Sarcopenia / Sarcopenic Obesity / Sedentary Lifestyle1
1, 2RecruitingBasic ScienceOxytocin1
1, 2TerminatedTreatmentChildhood Onset Psychotic Disorders / Schizophrenic Disorders1
2Active Not RecruitingOtherSchizophrenic Disorders1
2Active Not RecruitingTreatmentAutism Spectrum Conditions/Disorders1
2Active Not RecruitingTreatmentHyperphagia / Prader-Willi Syndrome1
2Active Not RecruitingTreatmentObstetric Labor1
2CompletedNot AvailablePost Traumatic Stress Disorder (PTSD)1
2CompletedBasic ScienceFocus of Study: Neural Correlates of Oxytocin Administration1
2CompletedBasic ScienceSocial Interactions1
2CompletedOtherAutism Spectrum Conditions/Disorders1
2CompletedOtherBody Dysmorphic Disorders / Obsessive Compulsive Disorder (OCD)1
2CompletedOtherDependence, Cocaine1
2CompletedOtherInterpersonal Conflict / Neuroendocrine Reactivity / Substance Misuse1
2CompletedPreventionPostpartum Haemorrhage (PPH)1
2CompletedScreeningPostpartum Haemorrhage (PPH)1
2CompletedTreatmentAlcohol Use Disorder (AUD)1
2CompletedTreatmentAutism Spectrum Conditions/Disorders4
2CompletedTreatmentAutism Spectrum Conditions/Disorders / Autism, Early Infantile1
2CompletedTreatmentAutism, Early Infantile2
2CompletedTreatmentChronic Migraine / High Frequency Episodic Migraine and Chronic Migraine1
2CompletedTreatmentEmotional Intelligence / Social Anxiety / Social Cognition1
2CompletedTreatmentFemale Sexual Dysfunction (FSD)1
2CompletedTreatmentFragile X Syndrome (FXS)1
2CompletedTreatmentFrontotemporal Dementia1
2CompletedTreatmentInduction of Labour1
2CompletedTreatmentPost Traumatic Stress Disorder (PTSD)1
2CompletedTreatmentPrader Willi Syndrome1
2CompletedTreatmentProlonged Labour1
2CompletedTreatmentSchizophrenic Disorders2
2CompletedTreatmentVulvovaginal Atrophy2
2CompletedTreatmentOne to five years postmenopausal / Vulvovaginal Atrophy1
2Enrolling by InvitationBasic ScienceAlcohol Abuse / Alcohol Use Disorder (AUD) / Anxiety Disorders / Post Traumatic Stress Disorder (PTSD) / Substance Use Disorder (SUD)1
2Enrolling by InvitationBasic ScienceAnxiety Disorders / Postpartum Depression / Stress, Psychological1
2Not Yet RecruitingBasic ScienceWeight gain therapy1
2Not Yet RecruitingPreventionPost Anaesthetic Shivering1
2Not Yet RecruitingTreatmentAlcohol Use Disorder (AUD)1
2Not Yet RecruitingTreatmentAutism Spectrum Conditions/Disorders2
2Not Yet RecruitingTreatmentBMI >30 kg/m21
2Not Yet RecruitingTreatmentDepression, Anxiety1
2RecruitingBasic ScienceAlcohol Use Disorder (AUD) / Healthy Controls / Non-social Motivation / Social Motivation1
2RecruitingBasic ScienceHealthy Volunteer Study1
2RecruitingBasic ScienceMaternal Behavior1
2RecruitingBasic SciencePain, Neuropathic1
2RecruitingPreventionFeeling Anxious / Postpartum Depression / Posttraumatic Stress Disorders1
2RecruitingPreventionPostpartum Haemorrhage (PPH)1
2RecruitingTreatmentAlcohol Dependence / Alcohol Withdrawal Syndrome(AWS)1
2RecruitingTreatmentAlcohol Use1
2RecruitingTreatmentAttachement Style1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders2
2RecruitingTreatmentBMI >30 kg/m21
2RecruitingTreatmentCocaine Use & Co-occuring Opioid Use Disorders / Stimulant Use Disorder1
2RecruitingTreatmentCocaine Use Disorders1
2RecruitingTreatmentDepressive Disorders1
2RecruitingTreatmentFrontotemporal Dementia1
2RecruitingTreatmentHyperphagia / Prader-Willi Syndrome1
2RecruitingTreatmentHypothalamic Obesity / Postsurgical craniopharyngioma1
2RecruitingTreatmentInduction of Labour / Oxytocin1
2RecruitingTreatmentIntemittant, Continue, Oxytocin1
2RecruitingTreatmentMoods Disorders / Oppositional Defiant Disorder1
2RecruitingTreatmentPhelan-McDermid Syndrome1
2RecruitingTreatmentPostoperative pain1
2SuspendedBasic ScienceCancer, Breast / Ductal Carcinoma In Situ1
2TerminatedTreatmentFetal Membranes, Premature Rupture / Induction of Labour1
2Unknown StatusBasic ScienceThe Impact of Oxytocin on Social Cognition1
2Unknown StatusTreatmentOxytocin + Non Specific Counselling / Oxytocin + Social Skills Training / Placebo + Non Specific Counselling / Placebo + Social Skills Training1
2Unknown StatusTreatmentSchizophrenic Disorders1
2WithdrawnTreatmentAutism Spectrum Conditions/Disorders1
2, 3Active Not RecruitingTreatmentPremenstrual Dysphoric Disorder1
2, 3CompletedPreventionCesarean Section1
2, 3CompletedTreatmentDependence, Cocaine1
2, 3Not Yet RecruitingTreatmentMyocardial Infarction1
2, 3Not Yet RecruitingTreatmentPain, Chronic / Pelvic Pain1
2, 3RecruitingTreatmentPrader-Willi Syndrome1
2, 3SuspendedTreatmentAutism Spectrum Conditions/Disorders1
3Active Not RecruitingTreatmentASD / Autism Spectrum Conditions/Disorders / PDD / Pervasive Developmental Disorder NOS1
3Active Not RecruitingTreatmentFetus or Newborn or Maternal; Effects of Induction of Labor1
3Active Not RecruitingTreatmentPostpartum Haemorrhage (PPH)1
3CompletedNot AvailableInduction / Labour / PROM (Pregnancy)1
3CompletedBasic ScienceHealthy Volunteers1
3CompletedPreventionComplications; Cesarean Section1
3CompletedPreventionPostpartum Haemorrhage (PPH)3
3CompletedTreatmentAlcohol Dependence / Substance-Related Disorders1
3CompletedTreatmentCervical Ripening / Induction of Labour / Multiparity1
3CompletedTreatmentPost Partum Hemorrhage1
3CompletedTreatmentPostpartum Haemorrhage (PPH)1
3Enrolling by InvitationTreatmentAlcohol Dependence / Substance-Related Disorders1
3Not Yet RecruitingPreventionUterine Hemorrhage1
3Not Yet RecruitingTreatmentInduction of Labour1
3Not Yet RecruitingTreatmentPost-Partum Hemorrhage1
3Not Yet RecruitingTreatmentPostpartum Haemorrhage (PPH)1
3RecruitingBasic ScienceAutism Spectrum Conditions/Disorders1
3RecruitingPreventionCesarean Section During Labor1
3RecruitingPreventionPost Partum Hemorrhage2
3RecruitingPreventionPostpartum Haemorrhage (PPH)1
3RecruitingTreatmentPoor; Labor1
3RecruitingTreatmentPost Partum Hemorrhage1
3SuspendedTreatmentPostpartum Haemorrhage (PPH)1
3TerminatedTreatmentLabour Dystocia1
3Unknown StatusPreventionPostpartum Haemorrhage (PPH) / Severe Preeclampsia1
3Unknown StatusTreatmentSchizophrenic Disorders1
3WithdrawnPreventionPostpartum Haemorrhage (PPH)1
4Active Not RecruitingDiagnosticHyperbilirubinemia in neonates1
4Active Not RecruitingTreatmentHealthy Volunteers1
4Active Not RecruitingTreatmentPost Traumatic Stress Disorder (PTSD)1
4CompletedNot AvailableAnxiety Disorders / Posttraumatic Stress Disorders / Reconsolidation1
4CompletedBasic ScienceHealth1
4CompletedBasic ScienceSocial Behavior1
4CompletedPreventionPostpartum Haemorrhage (PPH)2
4CompletedPreventionPostpartum Haemorrhage (PPH) / Uterine Atony1
4CompletedPreventionUterine Atony1
4CompletedTreatmentAOD Use, Abuse, and Dependence1
4CompletedTreatmentAnemias / Haemorrhage1
4CompletedTreatmentArterial Hypotension / Bloodloss / Myocardial Ischemia1
4CompletedTreatmentArterial Hypotension / Uterine Atony1
4CompletedTreatmentEffects of; Anesthesia, in Pregnancy1
4CompletedTreatmentInduction of Labour1
4CompletedTreatmentLabor Augmentation1
4CompletedTreatmentLabor; Forced or Induced, Affecting Fetus or Newborn1
4CompletedTreatmentMaternal Care for Late Fetal Death / Pregnancy, Cornual1
4CompletedTreatmentMissed Abortion1
4CompletedTreatmentSchizophrenic Disorders1
4CompletedTreatmentThird Stage of Labour1
4Enrolling by InvitationTreatmentAutism Spectrum Conditions/Disorders1
4Not Yet RecruitingPreventionBlood Loss Anemia / Uterine Atony With Hemorrhage1
4Not Yet RecruitingPreventionDelayed labour1
4Not Yet RecruitingPreventionPost Partum Hemorrhage1
4Not Yet RecruitingPreventionPostpartum Haemorrhage (PPH)1
4Not Yet RecruitingTreatmentInduction of Labour1
4Not Yet RecruitingTreatmentPremature Rupture of Fetal Membranes1
4RecruitingBasic ScienceNicotine Dependence / Tobacco Smoking Behavior1
4RecruitingOtherBMI >30 kg/m2 / Induction of Labour / Oxytocin1
4RecruitingPreventionAdverse Reaction to Oxytocin1
4RecruitingPreventionPostpartum Haemorrhage (PPH)1
4RecruitingTreatmentBleed Pregnancy / Blood Loss,Surgical / Cesarean Section Complications / Postpartum Haemorrhage (PPH) / Pregnancy Related1
4RecruitingTreatmentFailed Induction (of Labor) by Oxytocin1
4RecruitingTreatmentLabor Stage, Third/Drug Effects / Oxytocin/Administration & Dosage / Pregnancy Termination / Pregnancy Trimester, Second1
4TerminatedTreatmentCesarean Section / Vaginal Delivery1
4TerminatedTreatmentSubstance, Addiction1
4Unknown StatusPreventionCarbetocin for prevention of placental retained1
4Unknown StatusTreatmentLabour1
4WithdrawnPreventionPostpartum Haemorrhage (PPH) / Uterine Atony1
4WithdrawnTreatmentPostpartum Haemorrhage (PPH) / Uterine Atony1
Not AvailableActive Not RecruitingTreatmentASD / Autism Spectrum Conditions/Disorders / PDD / Pervasive Developmental Disorder NOS1
Not AvailableActive Not RecruitingTreatmentDystocia1
Not AvailableActive Not RecruitingTreatmentSchizophrenic Disorders1
Not AvailableCompletedNot AvailableBonding / Breastfeeding / Newborns / Oxytocin / Perinatal1
Not AvailableCompletedNot AvailableCoping Skills / Oxytocin / Stress1
Not AvailableCompletedNot AvailableOxytocin / Pregnancy1
Not AvailableCompletedNot AvailablePreeclampsia1
Not AvailableCompletedNot AvailableScarred Uterus1
Not AvailableCompletedNot AvailableSepsis1
Not AvailableCompletedBasic ScienceHealthy Volunteers8
Not AvailableCompletedBasic ScienceIntrusive Memories1
Not AvailableCompletedBasic ScienceMechanisms and Modulators of Placebo Analgesia in Healthy Volunteers1
Not AvailableCompletedBasic ScienceOxytocin / Placebo1
Not AvailableCompletedBasic SciencePosttraumatic Stress Disorders1
Not AvailableCompletedBasic ScienceSocial Behavior2
Not AvailableCompletedBasic ScienceSocial Intelligence1
Not AvailableCompletedBasic ScienceSubstance, Addiction1
Not AvailableCompletedDiagnosticImpact of Oxytocin on Social Learning1
Not AvailableCompletedHealth Services ResearchNeonatal Asphyxia / Postpartum Haemorrhage (PPH)1
Not AvailableCompletedOtherDependence, Cocaine1
Not AvailableCompletedOtherSchizophrenia Spectrum1
Not AvailableCompletedPreventionBlood Loss,Surgical1
Not AvailableCompletedPreventionComplications; Cesarean Section1
Not AvailableCompletedPreventionPlacenta, Retained / Postpartum Haemorrhage (PPH)1
Not AvailableCompletedPreventionPostpartum Haemorrhage (PPH)4
Not AvailableCompletedPreventionProlonged First Stage Labor - Prevention1
Not AvailableCompletedTreatmentAdverse Effect of Oxytocic Drugs / Inappropriate Dose of Drug Administered / Uterine Hemorrhage1
Not AvailableCompletedTreatmentAdverse Reaction to Oxytocin / Complications; Cesarean Section1
Not AvailableCompletedTreatmentAnaesthesia / Pregnancy Related1
Not AvailableCompletedTreatmentAutism Spectrum Conditions/Disorders1
Not AvailableCompletedTreatmentBirth; Delayed1
Not AvailableCompletedTreatmentBlood Loss / Dilation and Evacuation / Hemorrhage / Pregnancy termination therapy1
Not AvailableCompletedTreatmentCervical Ripening / Induction of Labour / Pregnancy1
Not AvailableCompletedTreatmentCervical Ripening / Premature Rupture of Membranes1
Not AvailableCompletedTreatmentCesarean Delivery / Induction of Uterine contractions1
Not AvailableCompletedTreatmentChronic Daily Headache1
Not AvailableCompletedTreatmentChronic Tinnitus1
Not AvailableCompletedTreatmentFrontotemporal Dementia / Pick's Disease1
Not AvailableCompletedTreatmentHeart; Disease,Complicating Pregnancy, Pre-existing1
Not AvailableCompletedTreatmentIdiopathic Infertility1
Not AvailableCompletedTreatmentIndigestion / Lack of Satiety1
Not AvailableCompletedTreatmentInduction of Labor in Multiparous Women1
Not AvailableCompletedTreatmentInduction of Labour1
Not AvailableCompletedTreatmentInterstitial Cystitis1
Not AvailableCompletedTreatmentMarijuana Dependence2
Not AvailableCompletedTreatmentNicotine Dependence1
Not AvailableCompletedTreatmentPostpartum Haemorrhage (PPH)9
Not AvailableCompletedTreatmentPregnancy Termination1
Not AvailableCompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableEnrolling by InvitationBasic ScienceHealthy Volunteers1
Not AvailableEnrolling by InvitationPreventionBlood Loss / Dysfunctional Labor / Uterine Atony1
Not AvailableNot Yet RecruitingNot AvailableCervical Ripening1
Not AvailableNot Yet RecruitingBasic ScienceHealthy Volunteers1
Not AvailableNot Yet RecruitingPreventionCesarean Section Complications1
Not AvailableNot Yet RecruitingTreatmentPremature Rupture of Membranes / Unfavorable Cervix1
Not AvailableNot Yet RecruitingTreatmentSchizophrenic Disorders1
Not AvailableRecruitingBasic ScienceBorderline Personality Disorder (BPD) / Effects of Oxytocin on Borderline Personality Disorder1
Not AvailableRecruitingBasic ScienceEmotions / Mental Health Wellness 1 / Social Behavior1
Not AvailableRecruitingBasic ScienceHealthy Volunteers5
Not AvailableRecruitingBasic ScienceInteroception1
Not AvailableRecruitingBasic ScienceMaternal Behavior1
Not AvailableRecruitingOtherBorderline Personality Disorder (BPD)1
Not AvailableRecruitingOtherSleep Apnea and Cardiovascular Diseases / Sleep Apnea Syndrome1
Not AvailableRecruitingPreventionCesarean Section Complications1
Not AvailableRecruitingPreventionDelayed Umbilical Cord Clamping Benefits / Intraventricular Hemorrhage / Postpartum Haemorrhage (PPH)1
Not AvailableRecruitingPreventionMaternal Infection During Pregnancy (Diagnosis) / Neonatal Infections1
Not AvailableRecruitingPreventionPostpartum Bleeding1
Not AvailableRecruitingPreventionPregnancy / Premature Rupture of Membranes / Preterm Premature Rupture of Membranes1
Not AvailableRecruitingTreatmentCesarean Section / Prophylaxis of preeclampsia1
Not AvailableRecruitingTreatmentFailed Induction of Labor2
Not AvailableRecruitingTreatmentInduction of Labour1
Not AvailableRecruitingTreatmentLabor; Forced or Induced, Affecting Fetus or Newborn / Pregnancy1
Not AvailableRecruitingTreatmentLabour Pain / Pregnancy1
Not AvailableRecruitingTreatmentMedical Induction of Labor Affecting Newborn1
Not AvailableRecruitingTreatmentPostpartum Haemorrhage (PPH)6
Not AvailableRecruitingTreatmentPrader-Willi Syndrome2
Not AvailableRecruitingTreatmentPremature Rupture of Fetal Membranes1
Not AvailableSuspendedTreatmentAnxiety Disorders1
Not AvailableSuspendedTreatmentSchizophrenic Disorders2
Not AvailableTerminatedTreatmentDysthymia Disorder / Major Depressive Disorder (MDD)1
Not AvailableUnknown StatusBasic ScienceASD / Autism, Early Infantile1
Not AvailableUnknown StatusBasic ScienceHealthy Volunteers1
Not AvailableUnknown StatusBasic SciencePsychiatric Disorders1
Not AvailableUnknown StatusDiagnosticPostpartum Depression1
Not AvailableUnknown StatusPreventionPost Traumatic Stress Disorder (PTSD)1
Not AvailableUnknown StatusPreventionPrevention of Post Partum Haemorrhage1
Not AvailableUnknown StatusTreatmentCervix; Insufficient Dilatation in Labor1
Not AvailableUnknown StatusTreatmentInduction of Labour / Pregnancy1
Not AvailableUnknown StatusTreatmentParanoia / Schizophrenic Disorders / Social Cognition Deficits / Social Dysfunction1
Not AvailableUnknown StatusTreatmentPostpartum Haemorrhage (PPH)1
Not AvailableUnknown StatusTreatmentInduction of Uterine contractions1
Not AvailableWithdrawnBasic ScienceCoagulation Changes With Oxytocin1
Not AvailableWithdrawnBasic SciencePain NOS1
Not AvailableWithdrawnBasic ScienceSchizophrenic Disorders1


  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia critical care
  • Teva parenteral medicines inc
  • Abbott laboratories pharmaceutical products div
  • Jhp pharmaceuticals llc
  • Novartis pharmaceuticals corp
  • APP Pharmaceuticals
  • BAM Biotech
  • Baxter International Inc.
  • Bimeda Inc.
  • Cardinal Health
  • Central Admixture Pharmacy Services
  • Gallipot
  • Gland Pharma Ltd.
  • Hikma Pharmaceuticals
  • JHP Pharmaceuticals LLC
  • Monarch Pharmacy
  • MWI Veterinary Supply Co.
  • Osburn Drug Co.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmakon
  • Pharmedium
  • Teva Pharmaceutical Industries Ltd.
  • Vedco Inc.
  • Watson Pharmaceuticals
Dosage forms
InjectionIntramuscular; Intravascular100 [USP'U]/10mL
InjectionIntravenous10 [USP'U]/1mL
InjectionIntravenous10 [iU]/1mL
InjectionIntravenous100 [USP'U]/10mL
Injection, solutionIntramuscular; Intravenous10 [USP'U]/1mL
Injection, solutionIntravenous10 [USP'U]/1000mL
Injection, solutionIntravenous10 [USP'U]/500mL
Injection, solutionIntravenous2 [USP'U]/100mL
Injection, solutionIntravenous20 [USP'U]/500mL
Injection, solutionIntravenous20 [USP'U]/1000mL
Injection, solutionIntravenous30 [USP'U]/1000mL
Injection, solutionIntravenous30 [USP'U]/500mL
LiquidIntramuscular; Intravenous10 unit
SolutionIntramuscular; Intravenous10 unit
InjectionIntramuscular; Intravenous10 [USP'U]/1mL
Injection, solutionIntramuscular; Intravenous10 [iU]/1mL
Unit descriptionCostUnit
Oxytocin powder1762.25USD g
Oxytocin 10 unit/ml vial9.84USD vial
Pitocin 10 unit/ml vial1.6USD ml
Oxytocin-lr 40 unit/500 ml0.09USD ml
Oxytocin-d5w-lr 40 unit/500 ml0.07USD ml
Oxytocin-d5lr 30 unit/500 ml0.06USD ml
Oxytocin-lr 20 unit/500 ml0.06USD ml
Oxytocin-d5w-lr 15 unit/500 ml0.05USD ml
Oxytocin-d5w-lr 20 unit/500 ml0.05USD ml
Oxytocin-lr 10 unit/500 ml0.05USD ml
Oxytocin-d5-1/4ns 15 unit/2500.04USD ml
Oxytocin-d5w 40 unit/1000 ml0.04USD ml
Oxytocin-d5w-lr 10 unit/500 ml0.04USD ml
Oxytocin-d5w 20 unit/1000 ml0.03USD ml
Oxytocin-d5w 30 unit/1000 ml0.03USD ml
Oxytocin-lr 30 unit/500 ml0.03USD ml
Oxytocin-ns 30 unit/1000 ml0.03USD ml
Oxytocin-d5w 10 unit/1000 ml0.02USD ml
Oxytocin-lr 5 unit/500 ml0.02USD ml
Oxytocin-ns 40 unit/1000 ml0.02USD ml
Oxytocin-d5-1/2ns 10 unit/10000.01USD ml
Oxytocin-d5-1/2ns 20 unit/10000.01USD ml
Oxytocin-d5-1/2ns 30 unit/10000.01USD ml
Oxytocin-d5-ns 20 unit/1000 ml0.01USD ml
Oxytocin-ns 10 unit/1000 ml0.01USD ml
Oxytocin-ns 20 unit/1000 ml0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Not Available


Experimental Properties
hydrophobicity-2.7Not Available
isoelectric point5.51Not Available


Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available


1. Oxytocin receptor
Pharmacological action
General Function
Vasopressin receptor activity
Specific Function
Receptor for oxytocin. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system.
Gene Name
Uniprot ID
Uniprot Name
Oxytocin receptor
Molecular Weight
42770.99 Da
  1. Spyranti Z, Fragiadaki M, Magafa V, Borovickova L, Spyroulias GA, Cordopatis P, Slaninova J: In position 7 L- and D-Tic-substituted oxytocin and deamino oxytocin: NMR study and conformational insights. Amino Acids. 2010 Jul;39(2):539-48. doi: 10.1007/s00726-009-0470-1. Epub 2010 Jan 27. [PubMed:20108008]
  2. Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M: Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. J Med Chem. 2010 Feb 25;53(4):1546-62. doi: 10.1021/jm901084f. [PubMed:20104850]
  3. Gimpl G, Reitz J, Brauer S, Trossen C: Oxytocin receptors: ligand binding, signalling and cholesterol dependence. Prog Brain Res. 2008;170:193-204. doi: 10.1016/S0079-6123(08)00417-2. [PubMed:18655883]
  4. Ahn TG, Han SJ, Cho YS, An TH, Pak SC, Flouret G: In vivo activity of the potent oxytocin antagonist on uterine activity in the rat. In Vivo. 2004 Nov-Dec;18(6):763-6. [PubMed:15646817]
  5. Furman DJ, Chen MC, Gotlib IH: Variant in oxytocin receptor gene is associated with amygdala volume. Psychoneuroendocrinology. 2011 Jul;36(6):891-7. doi: 10.1016/j.psyneuen.2010.12.004. Epub 2011 Jan 3. [PubMed:21208749]
Pharmacological action
General Function
Not Available
Specific Function
Neurophysin 1 specifically binds oxytocin.Oxytocin causes contraction of the smooth muscle of the uterus and of the mammary gland.
Gene Name
Uniprot ID
Uniprot Name
Oxytocin-neurophysin 1
Molecular Weight
12721.51 Da
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Land H, Grez M, Ruppert S, Schmale H, Rehbein M, Richter D, Schutz G: Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA. Nature. 1983 Mar 24-30;302(5906):342-4. [PubMed:6687626]
  3. Rao VV, Loffler C, Battey J, Hansmann I: The human gene for oxytocin-neurophysin I (OXT) is physically mapped to chromosome 20p13 by in situ hybridization. Cytogenet Cell Genet. 1992;61(4):271-3. [PubMed:1486803]


Pharmacological action
General Function
Serine-type peptidase activity
Specific Function
Cleaves peptide bonds on the C-terminal side of prolyl residues within peptides that are up to approximately 30 amino acids long.
Gene Name
Uniprot ID
Uniprot Name
Prolyl endopeptidase
Molecular Weight
80698.945 Da
  1. Irazusta J, Silveira PF, Gil J, Varona A, Casis L: Effects of hydrosaline treatments on prolyl endopeptidase activity in rat tissues. Regul Pept. 2001 Sep 15;101(1-3):141-7. [PubMed:11495689]
  2. Bausback HH, Ward PE: Vascular, post proline cleaving enzyme: metabolism of vasoactive peptides. Adv Exp Med Biol. 1986;198 Pt A:397-404. [PubMed:3544718]
  3. Yoshimoto T, Nishimura T, Kita T, Tsuru D: Post-proline cleaving enzyme (prolyl endopeptidase) from bovine brain. J Biochem. 1983 Oct;94(4):1179-90. [PubMed:6361010]

Drug created on June 13, 2005 07:24 / Updated on December 14, 2018 12:38